Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
27 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Cerulean Pharma, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Cerulean Pharma, Inc. - Product Pipeline Review - 2014', provides an overview of the Cerulean Pharma, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Cerulean Pharma, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Cerulean Pharma, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Cerulean Pharma, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Cerulean Pharma, Inc.'s pipeline products Reasons to buy - Evaluate Cerulean Pharma, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Cerulean Pharma, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Cerulean Pharma, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Cerulean Pharma, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cerulean Pharma, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Cerulean Pharma, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 Cerulean Pharma, Inc. Snapshot 4 Cerulean Pharma, Inc. Overview 4 Key Information 4 Key Facts 4 Cerulean Pharma, Inc. - Research and Development Overview 5 Key Therapeutic Areas 5 Cerulean Pharma, Inc. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Cerulean Pharma, Inc. - Pipeline Products Glance 9 Cerulean Pharma, Inc. - Clinical Stage Pipeline Products 9 Phase II Products/Combination Treatment Modalities 9 Phase I Products/Combination Treatment Modalities 10 Cerulean Pharma, Inc. - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Cerulean Pharma, Inc. - Drug Profiles 12 CRLX-101 12 Product Description 12 Mechanism of Action 12 R&D Progress 12 docetaxel nanoparticles 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 RNAi Oligonucleotide for Breast Cancer 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Cerulean Pharma, Inc. - Pipeline Analysis 16 Cerulean Pharma, Inc. - Pipeline Products by Target 16 Cerulean Pharma, Inc. - Pipeline Products by Route of Administration 17 Cerulean Pharma, Inc. - Pipeline Products by Molecule Type 18 Cerulean Pharma, Inc. - Pipeline Products by Mechanism of Action 19 Cerulean Pharma, Inc. - Recent Pipeline Updates 20 Cerulean Pharma, Inc. - Dormant Projects 24 Cerulean Pharma, Inc. - Locations And Subsidiaries 25 Head Office 25 Appendix 26 Methodology 26 Coverage 26 Secondary Research 26 Primary Research 26 Expert Panel Validation 26 Contact Us 27 Disclaimer 27
List of Tables Cerulean Pharma, Inc., Key Information 4 Cerulean Pharma, Inc., Key Facts 4 Cerulean Pharma, Inc. - Pipeline by Indication, 2014 6 Cerulean Pharma, Inc. - Pipeline by Stage of Development, 2014 7 Cerulean Pharma, Inc. - Monotherapy Products in Pipeline, 2014 8 Cerulean Pharma, Inc. - Phase II, 2014 9 Cerulean Pharma, Inc. - Phase I, 2014 10 Cerulean Pharma, Inc. - Preclinical, 2014 11 Cerulean Pharma, Inc. - Pipeline by Target, 2014 16 Cerulean Pharma, Inc. - Pipeline by Route of Administration, 2014 17 Cerulean Pharma, Inc. - Pipeline by Molecule Type, 2014 18 Cerulean Pharma, Inc. - Pipeline Products by Mechanism of Action, 2014 19 Cerulean Pharma, Inc. - Recent Pipeline Updates, 2014 20 Cerulean Pharma, Inc. - Dormant Developmental Projects,2014 24
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.